Unknown

Dataset Information

0

A Cross-Protective Vaccine Against 4b and 1/2b Listeria monocytogenes.


ABSTRACT: Listeria monocytogenes (Lm) is a foodborne zoonotic pathogen that causes listeriosis with a mortality rate of 20-30%. Serovar 4b and 1/2b isolates account for most of listeriosis outbreaks, however, no listeriosis vaccine is available for either prophylactic or therapeutic use. Here, we developed a triple-virulence-genes deletion vaccine strain, and evaluated its safety, immunogenicity, and cross-protective efficiency. The virulence of NTSN?actA/plcB/orfX was reduced 794-folds compared with the parental strain. Additionally, it was completely eliminated in mice at day 7 post infection and no obvious pathological changes were observed in the organs of mice after prime-boost immunization for 23 days. These results proved that the safety of the Lm vaccine strain remarkably increased. More importantly, the NTSN?actA/plcB/orfX strain stimulated higher anti-Listeriolysin O (LLO) antibodies, induced significantly higher expression of IFN-?, TNF-?, IL-17, and IL-6 than the control group, and afforded 100% protection against serovar 4b and 1/2b challenges. Taken together, our research demonstrates that the triple-genes-deletion vaccine has high safety, can elicit strong Th1 type immune response, and affords efficient cross-protection against two serovar Lm strains. It is a promising vaccine for prevention of listeriosis.

SUBMITTER: Meng F 

PROVIDER: S-EPMC7759533 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

A Cross-Protective Vaccine Against 4b and 1/2b <i>Listeria monocytogenes</i>.

Meng Fanzeng F   Zhu Tengfei T   Yao Hao H   Ling Zhiting Z   Feng Youwei Y   Li Guo G   Li Jing J   Sun Xinyu X   Chen Jiaqi J   Meng Chuang C   Jiao Xin'an X   Yin Yuelan Y  

Frontiers in microbiology 20201211


<i>Listeria monocytogenes</i> (<i>Lm</i>) is a foodborne zoonotic pathogen that causes listeriosis with a mortality rate of 20-30%. Serovar 4b and 1/2b isolates account for most of listeriosis outbreaks, however, no listeriosis vaccine is available for either prophylactic or therapeutic use. Here, we developed a triple-virulence-genes deletion vaccine strain, and evaluated its safety, immunogenicity, and cross-protective efficiency. The virulence of NTSNΔ<i>actA</i>/<i>plcB</i>/<i>orfX</i> was r  ...[more]

Similar Datasets

| S-EPMC7788512 | biostudies-literature
| S-EPMC5721137 | biostudies-literature
| S-EPMC3929640 | biostudies-literature
| S-EPMC9562072 | biostudies-literature
| S-EPMC8070769 | biostudies-literature
| S-EPMC3434726 | biostudies-literature
2022-09-26 | PXD031451 | Pride
| S-EPMC3264116 | biostudies-literature
| S-EPMC3563664 | biostudies-literature
| S-EPMC4299896 | biostudies-literature